Format

Send to

Choose Destination
Trends Pharmacol Sci. 1992 Jun;13(6):256-62.

Receptor sites for Ca2+ channel antagonists.

Author information

1
Department of Pharmacology, University of Washington, Seattle 98195.

Abstract

Ca2+ channel antagonist drugs inhibit voltage-gated Ca2+ channels in many different cell types. Inhibition of Ca2+ channels in smooth muscle and cardiac muscle cells by these drugs is valuable in the therapy of a wide range of cardiovascular disorders including hypertension, atrial arrhythmia and angina pectoris. Additional uses under evaluation are protection against ischemic damage during myocardial infarction and stroke and in a wide range of other conditions. Further understanding of the sites and mechanisms of action of Ca2+ channel antagonists, as described in this review by Bill Catterall and Jörg Striessnig, will provide new insight into the design of novel therapeutic agents acting on Ca2+ channels and provide further understanding of Ca2+ channel structure and function.

PMID:
1321525
DOI:
10.1016/0165-6147(92)90079-l
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center